Quantcast
Home > Quotes > UROV

Urovant Sciences Ltd. Common Stock (UROV) Quote & Summary Data

UROV 
$6.19
*  
0.25
3.88%
Get UROV Alerts
*Delayed - data as of Dec. 12, 2018  -  Find a broker to begin trading UROV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    UROV After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.83 / $ 14.32
1 Year Target
21
Today's High / Low
$ 6.53 / $ 5.99
Share Volume
84,937
50 Day Avg. Daily Volume
67,043
Previous Close
$ 6.44
52 Week High / Low
$ 14.32 / $ 6.25
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
84,937
50 Day Avg. Daily Volume:
67,043

Trading Range

The current last sale of $6.19 is -0.96% Lower than the 52 week low.

Intraday Last 52 Weeks
High: $ 6.53 $ 14.32
 Low: $ 5.99 $ 6.25

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate, vibegron, is an oral, once-daily, small molecule that was observed to be highly selective for the human beta-3 adrenergic receptor in in vitro assays. We are currently evaluating vibegron in our 1,400 patient, international pivotal Phase 3 clinical trial for the treatment of overactive bladder, or OAB. We expect to report top-line results from this clinical trial in the first or second quarter of 2019, and if the results are positive, we plan to submit a new drug application to the U.S. Food and Drug Administration, or FDA, by early 2020. OAB is a highly prevalent condition, with more than 30 million Americans over the age of 40 suffering from bothersome symptoms.  ... More ...  


Risk Grade

Where does UROV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 6.47
Open Date:
Dec. 12, 2018
Close Price:
$ 6.19
Close Date:
Dec. 12, 2018

Consensus Recommendation

Analyst Info